Will The Decline in Legacy Drugs Pull Down BMY's Top Line?

• click to rate

  Posted by Two Blokes Jul 3 - Filed in Stock - 5 views
  
  Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.